UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported) August 3, 2007
PHARMATHENE,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-32587
|
|
20-2726770
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
One
Park Place, Suite 450
Annapolis,
Maryland
|
|
21401
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number including area code: (410) 269-2600
Healthcare
Acquisition Corp.
2116
Financial Center 666 Walnut Street
Des
Moines, IA 50309
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230
.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
PharmAthene,
Inc. (the "Company") is filing this Current Report on Form 8-K (“Form 8-K”)
concurrently with a separate Form 8-K on this same date. However, both Form
8-Ks
are being filed in connection with the consummation of the Merger transaction
described in Items 1.01 and 2.01 of the other 8-K. These two Form 8-Ks are
filed
separately because the number of “Items” the Company must file in connection
with the consummation of its Merger transaction exceeds the nine (9) “Item”
limitation on the number of Items that can be included in one Form
8-K.
|
Item 2.03
|
Creation
of a Direct Financial Obligation.
|
Information
with respect to the Convertible Notes issued
in connection with the Merger is set forth in the Definitive Proxy Statement
beginning on page 80 and is incorporated herein by
reference.
|
Item 5.01
|
Change
in Control of Registrant.
|
Upon
the
consummation of the Merger, Former PharmAthene acquired control of the combined
corporation. See the description of the Merger set forth in the Definitive
Proxy
Statement commencing on page 57, which is incorporated herein by reference,
as
well as the description contained in Item 2.01 of this Current Report on Form
8-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
PHARMATHENE,
INC.
(registrant)
|
||
| |
|
|
|
August 9,
2007
|
By: |
/s/
David Wright
|
|
David
Wright
President
and Chief Executive Officer
|
||